Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Calorie restriction extends lifespan and produces a metabolic profile desirable for treating diseases of ageing such as type 2 diabetes. SIRT1, an NAD+-dependent deacetylase, is a principal modulator of pathways downstream of calorie restriction that produce beneficial effects on glucose homeostasis and insulin sensitivity. Resveratrol, a polyphenolic SIRT1 activator, mimics the anti-ageing effects of calorie restriction in lower organisms and in mice fed a high-fat diet ameliorates insulin resistance, increases mitochondrial content, and prolongs survival. Here we describe the identification and characterization of small molecule activators of SIRT1 that are structurally unrelated to, and 1,000-fold more potent than, resveratrol. These compounds bind to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. In diet-induced obese and genetically obese mice, these compounds improve insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. In Zucker fa/fa rats, hyperinsulinaemic-euglycaemic clamp studies demonstrate that SIRT1 activators improve whole-body glucose homeostasis and insulin sensitivity in adipose tissue, skeletal muscle and liver. Thus, SIRT1 activation is a promising new therapeutic approach for treating diseases of ageing such as type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finally, we show that recently developed SIRT1 activators, which are effective in improving energy homeostasis and decreasing hepatosteatosis in mouse models (Milne et al. 2007;Feige et al. 2008), also increase ubiquitination and proteasomal targeting of SREBP-1a, resulting in decreased SREBP-1 nuclear levels and target gene expression.”
From Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP (2010) · cites this paper as Milne et al. 2007
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent studies have reported the identification of potent SIRT1-activating compounds, and showed that such SIRT1 activators could significantly ameliorate insulin resistance and improve energy homeostasis in mouse diet-induced obesity models (Milne et al. 2007).”
From Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP (2010) · cites this paper as Milne et al. 2007
In the citing paper
“In contrast to these negative regulators of insulin action, SIRT1 appears to be a positive regulator of insulin sensitivity (43,44).”
From Insulin sensitivity: Modulation by nutrients and inflammation (2008) · cites this paper as [43]
In the citing paper
“Additionally, the non-naturally occurring sirtuin-activating compound, SRT1720, has enhanced insulin sensitivity and oxidative metabolism in animal models of obesity, in part, by improving mitochondrial oxidative capacity231.”
From Mitochondrial and metabolic dysfunction in ageing and age-related diseases (2022) · cites this paper as [231]
In the citing paper
“Other related small molecules are more potent than resveratrol to enhance the action of SIRT1 on substrates for deacetylation (218). These compounds also improve insulin sensitivity in obese rodents (218).”
From Mitochondrial Dysfunction in Diabetes: From Molecular Mechanisms to Functional Significance and Therapeutic Opportunities (2010) · cites this paper as [218]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Resveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Self-citationLagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057
Self-citationSmall molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L.-L., et al. (2003) · Nature · doi:10.1038/nature01960 · Cited by 3,796
Self-citationTranscriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510
Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., & Puigserver, P. (2005) · Nature · doi:10.1038/nature03354 · Cited by 3,160
hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659
Kaeberlein, M., McVey, M., & Guarente, L. (1999) · Genes & Development · doi:10.1101/gad.13.19.2570 · Cited by 2,253
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase
Cohen, H. Y., Miller, C., Bitterman, K. J., Wall, N. R., Hekking, B., Kessler, B., Howitz, K. T., Gorospe, M., de Cabo, R., & Sinclair, D. A. (2004) · Science · doi:10.1126/science.1099196 · Cited by 1,924
Self-citationSirtuin activators mimic caloric restriction and delay ageing in metazoans
Wood, J. G., Rogina, B., Lavu, S., Howitz, K., Helfand, S. L., Tatar, M., & Sinclair, D. (2004) · Nature · doi:10.1038/nature02789 · Cited by 1,868
Self-citation
Research works printed but not linked: 1
- Banks A, et al. Overexpression of the Sirtuin SIRT1 increases insulin sensitivity in aging mice. Diabetes. 2007;56(S1):0234-OR. [Google Scholar]
Cited by
Items 701–800 of 1,004
Pasco, M. Y., Rotili, D., Altucci, L., Farina, F., Rouleau, G. A., Mai, A., & Néri, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9013345 · Cited by 53
Joe, I.-S., Jeong, S., & Cho, G. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.10.024 · Cited by 53
Endurance Exercise Mimetics in Skeletal Muscle
Matsakas, A., & Narkar, V. A. (2010) · Current Sports Medicine Reports · doi:10.1249/jsr.0b013e3181e93938 · Cited by 50
“Recent studies confirm that potent and selective SIRT1 activators have similar effects as resveratrol via deacetylation of PGC-1> and additional transcriptional regulators such as FOXO1 and p53 (13,17,38).”
BackgroundWei, H., Zhang, Z., Saha, A., Peng, S., Chandra, G., Quezado, Z., & Mukherjee, A. B. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq555 · Cited by 53
FRUCTOSE INDUCES GLUCONEOGENESIS AND LIPOGENESIS THROUGH A SIRT1-DEPENDENT MECHANISM
Caton, P., Nayuni, N. K., Khan, N., Wood, E. G., & Corder, R. (2011) · Journal of Endocrinology · doi:10.1530/joe-10-0190 · Cited by 65
“SRT1720 has been described as a small molecule activator of SIRT1 (Milne et al. 2007), although a recent study has suggested that this compound is not a direct activator of SIRT1 and may act on multiple targets (Pacholec et al. 2010).”
BackgroundInfluentialThe importance of synthetic drugs for type 2 diabetes drug discovery
Safavi, M., Foroumadi, A., & Abdollahi, M. R. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.837883 · Cited by 60
“Recently, PPARa/ dual agonists [230], SIRT1 activators [231,232], glycogen phosphorylase inhibitors [233] and protein tyrosine phosphatase 1B inhibitors [233-235] were luckily designed for the treatment of T2DM.”
BackgroundSands, B. E., Joshi, S., Haddad, J., Freudenberg, J. M., Oommen, D. E., Hoffmann, E., McCallum, S. W., & Jacobson, E. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000597 · Cited by 51
Targeting Sirtuins: Substrate Specificity and Inhibitor Design
Rajabi, N., Galleano, I., Madsen, A. S., & Olsen, C. A. (2018) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.11.003 · Cited by 58
The Expanding Therapeutic Potential of Neuronal KCC2
Tang, B. L. (2020) · Cells · doi:10.3390/cells9010240 · Cited by 54
“SIRT1 activation by more specific activators like SRT1720 [128] has been shown to alleviate diabetic neuropathic pain [129].”
BackgroundKim, J., Kang, Y., Lee, J.-Y., Choi, D. H., Cho, Y., Shin, J.-M., Park, J. S., Lee, J. H., Kim, W. G., Seo, D. B., et al. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.05.006 · Cited by 55
“STACs, including resveratrol and more target-specific, chemically distinct molecules, have been developed over the past several years (Bemis et al., 2009; Milne et al., 2007; Vu et al., 2009).”
Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
Александровна, П. В., Bezborodkina, N. N., & Okovityi, S. V. (2022) · Biomedicines · doi:10.3390/biomedicines10020274 · Cited by 58
Sirtuins: double players in Huntington's disease
Naia, L., & Rego, A. C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.07.003 · Cited by 57
Inactivation of arf-bp1 Induces p53 Activation and Diabetic Phenotypes in Mice
Kon, N., Zhong, J., Qiang, L., Accili, D., & Gu, W. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.322867 · Cited by 52
“In this regard, it is also interesting to knowwhether small molecule activators of SirT1, a deacetylase of p53 (39, 40), can improve glucose homeostasis and insulin sensitivity, partially through modulating p53 function.”
BackgroundRejuvenating Sirtuins: The Rise of a New Family of Cancer Drug Targets
Bruzzone, S., Parenti, M. D., Grozio, A., Ballestrero, A., Bauer, I., Río, A. D., & Nencioni, A. (2012) · Current Pharmaceutical Design · doi:10.2174/138161213804581954 · Cited by 57
Targeting metabolic syndrome: Candidate natural agents
Xia, X., & Weng, J. (2010) · Journal of Diabetes · doi:10.1111/j.1753-0407.2010.00090.x · Cited by 55
SIRT1 in metabolic syndrome: Where to target matters
Wang, Y., Xu, C., Liang, Y., & Vanhoutte, P. M. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.08.009 · Cited by 56
The place of genetics in ageing research
Barzilai, N., Guarente, L., Kirkwood, T. B. L., Partridge, L., Rando, T. A., & Slagboom, P. E. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3290 · Cited by 59
SIRT1 Undergoes Alternative Splicing in a Novel Auto-Regulatory Loop with p53
Lynch, C. J., Shah, Z. H., Allison, S. J., Ahmed, S. U., Ford, J. R., Warnock, L. J., Li, H., Serrano, M., & Milner, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013502 · Cited by 57
“(B) Schematic of the 747-residue human SIRT1-Full-Length protein (SIRT1-FL; based on NP_036370) with the Exon8-encoded region highlighted (558bp, 186 residues, black) within the catalytic deacetylase domain (240-664, red) as defined by Sinclair and colleagues [2].”
Wei, D., Tao, R., Zhang, Y., White, M. F., & Dong, X. C. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00524.2010 · Cited by 51
“Recently, it has been reported that Sirt1 activators such as SRT1720 can improve type 2 diabetes by increasing systemic insulin sensitivity and mitochondrial capacity and by lowering hepatic glucose production in the Zucker fa/fa obese rat model (27); however, the specificity of SRT1720 is still a matter of debate (8,…”
Das, S. K., DesAulniers, J., Dyck, J. R. B., Kassiri, Z., & Oudit, G. Y. (2015) · Liver International · doi:10.1111/liv.12893 · Cited by 57
Wang, F., Shang, Y., Zhang, R., Gao, X., & Zeng, Q. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9699 · Cited by 51
Chattopadhyay, T., Maniyadath, B., Bagul, H. P., Chakraborty, A., Shukla, N., Budnar, S., Rajendran, A., Shukla, A., Kamat, S. S., & Kolthur‐Seetharam, U. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1909943117 · Cited by 55
“Given that there have been many attempts to create gain-of-function models of SIRT1 (15, 24, 27, 28, 74, 75), our study points out that uncontrolled (over)-activation of SIRT1, as in the case of hypoglycosylation, can have detrimental pathological consequences.”
BackgroundTherapeutic potential of activators and inhibitors of sirtuins
Balcerczyk, A., & Pirola, L. (2010) · BioFactors · doi:10.1002/biof.112 · Cited by 53
Gardner, P. J., Joshi, L., Lee, R., Dick, A. D., Adamson, P., & Calder, V. L. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.01.011 · Cited by 53
“SRT1460 and SRT2379 are small molecule activators of human SIRT1 that are structurally unrelated and 1000-fold more potent than resveratrol [20].”
BackgroundSIRT1 — a metabolic sensor that controls blood vessel growth
Guarani, V., & Potente, M. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.01.001 · Cited by 52
Peng, C., Cherng, J., Chiou, G., Chen, Y., Chien, C.-H., Kao, C.-L., Chang, Y.-L., Chien, Y., Chen, L., Liu, J., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.08.008 · Cited by 54
Natural Polyphenols and Apoptosis Induction in Cancer Therapy
Estrela, L. R. M. (2013) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.s6-004 · Cited by 57
“The knowledge and implications of these compounds in human health include beneficial effects in cancer [5052], neuroprotection [53,54], cardiovascular system dysfunction and damage [47,55], the metabolic syndrome [56,57], diabetes [58], aging [59,60], and different inflammation-related pathologies [60].”
BackgroundWang, Y., Chen, Y., Wang, H., Cheng, Y., & Zhao, X. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b01069 · Cited by 50
POLYPHENOLS AND HUMAN HEALTH- A REVIEW
Wani, S. M. (2013) · International Journal of Pharma and Bio Sciences · Cited by 55
Louvet, L., Leterme, D., Delplace, S., Miellot, F., Marchandise, P., Gauthier, V., Hardouin, P., Chauveau, C., & Ghali Mhenni, O. (2020) · Bone · doi:10.1016/j.bone.2020.115361 · Cited by 49
From a glucocentric to a lipocentric approach towards metabolic syndrome
Mittra, S., Bansal, V. S., & Bhatnagar, P. K. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.01.006 · Cited by 48
Nebbioso, M., Lambìase, A., Armentano, M., Tucciarone, G., Sacchetti, M., Greco, A., & Alisi, L. (2021) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2021.04.003 · Cited by 57
Potent and Specific Activators for Mitochondrial Sirtuins Sirt3 and Sirt5
Suenkel, B., Valente, S., Zwergel, C., Weiss, S., Bello, E. D., Fioravanti, R., Aventaggiato, M., Amorim, J. A., Garg, N., Kumar, S., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01215 · Cited by 52
Self-citationSRT1720 as an SIRT1 activator for alleviating paraquat-induced models of Parkinson's disease
Chao, C.-C., Huang, C., Cheng, J., Chiou, C., Lee, I., Yang, Y.-C., Hsu, T.-H., Yei, C.-E., Lin, P.-Y., Chen, J., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102534 · Cited by 56
“Originally, it has been synthesized by Sirtris Pharmaceuticals, aiming to treat type 2 diabetes [56] and extend lifespan [57].”
BackgroundMethodThe sirtuins: Markers of metabolic health
Covington, J. D., & Bajpeyi, S. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500340 · Cited by 54
White, A. T., Philp, A., Fridolfsson, H. N., Schilling, J. M., Murphy, A. N., Hamilton, D. L., McCurdy, C. E., Patel, H. H., & Schenk, S. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00001.2014 · Cited by 53
“Given the potential benefit of SIRT1 activation for the treatment of insulin resistance (16, 25, 26, 39), and the importance of skeletal muscle in postprandial glycemia (14), we investigated whether overexpression of SIRT1 in skeletal muscle is sufficient to prevent obesity-related impairments in glucose tolerance and…”
BackgroundSelf-citationTargeting aberrant cancer metabolism – The role of sirtuins
Kleszcz, R., Paluszczak, J., & Baer‐Dubowska, W. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.03.021 · Cited by 54
Sirtuin regulation in calorie restriction
Qiu, X., Brown, K. V., Moran, Y., & Chen, D. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.09.015 · Cited by 60
Rebollo, A., Roglans, N., Baena, M., Sánchez, R. M., Merlos, M., Alegret, M., & Laguna, J. C. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.01.002 · Cited by 53
“induced by incubating FaO cells with SRT1720, a potent and selective activator of SIRT1 [32] (Figure 6C).”
BackgroundThe Role of Sirtuins in Cartilage Homeostasis and Osteoarthritis
Dvir‐Ginzberg, M., Mobasheri, A., & Kumar, A. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0591-y · Cited by 54
Use of elicitors to enhance or activate the antibiotic production in streptomyces
Zong, G., Fu, J., Zhang, P., Zhang, W., Xu, Y., Cao, G., & Zhang, R. (2021) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2021.1987856 · Cited by 58
Afzaal, A., Rehman, K., Kamal, S., & Akash, M. S. H. (2022) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23047 · Cited by 50
GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119
Kang, S.-U. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.09.011 · Cited by 49
Extensive screening for herbal extracts with potent antioxidant properties
Niwano, Y., Saito, K., Yoshizaki, F., Kohno, M., & Ozawa, T. (2010) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.11-013fr · Cited by 58
Wang, T., Cui, H., MA, N., & Jiang, Y. (2013) · Oncology Letters · doi:10.3892/ol.2013.1400 · Cited by 53
The role of SirT1 in muscle mitochondrial turnover
Menzies, K. J., & Hood, D. A. (2011) · Mitochondrion · doi:10.1016/j.mito.2011.03.001 · Cited by 51
Yaseen, A. A., Chen, S., Hock, S. K., Rosato, R. R., Dent, P., Dai, Y., & Grant, S. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.079624 · Cited by 58
“According to this model, exposure of leukemia cells to resveratrol triggers multiple interrelated actions, including activation of Sirt1 (Milne et al., 2007), induction of ROS (Chandra, 2009), and synchronization of cells in the S-phase (Estrov et al., 2003).”
BackgroundInfluentialCarey, A. L., & Kingwell, B. A. (2009) · Diabetologia · doi:10.1007/s00125-009-1420-x · Cited by 53
“Novel SIRT1 activators have been developed [76, 77], with substantially greater potency than resveratrol; these can protect mice from diet-induced obesity and insulin insensitivity, and are among the most promising candidates for clinical application.”
BackgroundRetinoic acid ameliorates high-fat diet-induced liver steatosis through sirt1
Geng, C., Xu, H. C., Zhang, Y., Gao, Y., Li, M., Liu, X., Gao, M., Wang, X., Liu, X., Fang, F., et al. (2017) · Science China Life Sciences · doi:10.1007/s11427-016-9027-6 · Cited by 49
Ligand-Free Copper-Catalyzed Regioselective C-2 Arylation of Imidazo[2,1-b]thiazoles
Huang, G., Sun, H., Qiu, X., Jin, C., Chen, L., Shen, Y., Jiang, J., & Wang, L. (2011) · Organic Letters · doi:10.1021/ol2021109 · Cited by 48
Kang, H., Lee, Y., Bae, M., Park, Y.-K., & Lee, J.-Y. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2020.108477 · Cited by 48
Salinthone, S., Schillace, R. V., Marracci, G., BOURDETTE, D. N., & Carr, D. W. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.05.003 · Cited by 48
Naomi, R., Yazid, M. D., Teoh, S. H., Balan, S. S., Halim, S., Kumar, J., Bahari, H., & Embong, H. (2023) · Antioxidants · doi:10.3390/antiox12051054 · Cited by 59
Targeting sirtuins for the treatment of diabetes
Huynh, F. K., Hershberger, K. A., & Hirschey, M. D. (2013) · Diabetes Management · doi:10.2217/dmt.13.6 · Cited by 52
Liu, Z., Gan, L., Liu, G., Chen, Y., Wu, T., Feng, F., & Sun, C. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m063537 · Cited by 47
Human sirtuins: Structures and flexibility
Sacconnay, L., Carrupt, P., & Nurisso, A. (2016) · Journal of Structural Biology · doi:10.1016/j.jsb.2016.10.008 · Cited by 49
Solid-Phase Synthesis of Thiazolo[4,5-b]pyridine Derivatives Using Friedländer Reaction
Lee, T., Lee, D., Lee, I. Y., & Gong, Y. (2009) · Journal of Combinatorial Chemistry · doi:10.1021/cc900147y · Cited by 46
Understanding the acetylome: translating targeted proteomics into meaningful physiology
Philp, A., Rowland, T., Pérez‐Schindler, J., & Schenk, S. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00399.2013 · Cited by 52
Self-citationAbdelali, A., Al‐Bader, M., & Kilarkaje, N. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.09.023 · Cited by 46
Erratum to: Resveratrol and red wine, healthy heart and longevity
Das, D. K., Mukherjee, S., & Ray, D. (2011) · Heart Failure Reviews · doi:10.1007/s10741-011-9234-6 · Cited by 51
“Evidence is available to show the positive effects of resveratrol and SIRT1 activation on several age-related disorders including type-2 diabetes, cardiovascular disease, neuro-degeneration and inflammation [10, 61, 72, 73].”
Therapeutic effects of icariin and icariside II on diabetes mellitus and its complications
Jiang, W., Ding, K., Yue, R., & Lei, M. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2159317 · Cited by 47
“In excess nutrient diseases, usually caused by the intake of too much food or a nutrient that causes metabolic disorders in the body, such as obesity and DM, the SIRT1/AMPK axis is inhibited (Coughlan et al. 2014; Milne et al. 2007).”
BackgroundPolystyrene microplastics disturb maternal glucose homeostasis and induce adverse pregnancy outcomes
Zhang, R., Feng, Y., Nie, P., Wang, W., Wu, H., Wan, X., Xu, H., & Fu, F. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.116492 · Cited by 46
Sakkiah, S., Arooj, M., Cao, G. P., & Lee, K. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059278 · Cited by 47
“Small molecules that can modulate sirtuin activity have been shown to have potential in treating cancer [19,20], Parkinson’s disease [21], obesity and diabetes [22–25], aging and aging-related diseases [26] as well as it is a putative therapeutic target for affecting Huntington disease (HD) mediated transcriptional dy…”
BackgroundSIRT1 and Neural Cell Fate Determination
Cai, Y., Xu, L., Xu, H., & Fan, X. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9158-6 · Cited by 48
“have been reported to activate SIRT1 with potencies of 1000fold greater than resveratrol [44].”
BackgroundMitochondrial Targets for Pharmacological Intervention in Human Disease
Malty, R. H., Jessulat, M., Jin, K., Musso, G. A., Vlasblom, J., Phanse, S., Zhang, Z., & Babu, M. (2014) · Journal of Proteome Research · doi:10.1021/pr500813f · Cited by 47
Overexpression of SIRT1 in Mouse Forebrain Impairs Lipid/Glucose Metabolism and Motor Function
Wu, D., Qiu, Y., Gao, X., Yuan, X., & Zhai, Q. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021759 · Cited by 46
“insulin sensitivity, prevented the development of fatty liver and/or increased mitochondrial activity in the brown adipose tissue (BAT) and muscle [13,14,15].”
Histone deacetylases as transducers and targets of nuclear signaling
Walkinshaw, D. R., Tahmasebi, S., Bertos, N., & Yang, X. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21746 · Cited by 54
Wang, Q., Liu, M., Liu, W., Hao, W., Tashiro, S., Onodera, S., & Ikejima, T. (2012) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2012.657180 · Cited by 45
Sirt1's systemic protective roles and its promise as a target in antiaging medicine
Tang, B. L. (2010) · Translational research · doi:10.1016/j.trsl.2010.11.006 · Cited by 48
Bizat, N., Peyrin, J.-M., Haïk, S., Cochois, V., Beaudry, P., Laplanche, J.-L., & Néri, C. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5831-09.2010 · Cited by 45
“Future studies will address the activity of SIRT1selective activators (Milne et al., 2007; Feige et al., 2008) in this respect.”
BackgroundAMPK-associated signaling to bridge the gap between fuel metabolism and hepatocyte viability
Yang, Y. M., Han, C. Y., Kim, Y. J., & Kim, S. G. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i30.3731 · Cited by 50
Resveratrol Protects against Methylglyoxal-Induced Hyperglycemia and Pancreatic Damage In Vivo
Cheng, A.-S., Cheng, Y.-H., Lee, C., Chung, C.-Y., & Chang, W.-C. (2015) · Nutrients · doi:10.3390/nu7042850 · Cited by 45
“It acts through multiple pathways, including AMP-activated protein kinase (AMPK), sirtuin 1 (SIRT1) and nuclear factor erythroid 2-related factor 2 (Nrf2), to protect against pancreatic β-cell dysfunction and improve insulin sensitivity [24–28].”
BackgroundRumpf, T., Gerhardt, S., Einsle, O., & Jung, M. (2015) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x15019986 · Cited by 49
“Thus, they are involved in the regulation of cell-cycle control (Vaquero et al., 2007; ISSN 2053-230X Serrano et al., 2013), metabolism (Hirschey et al., 2010), stress response (Bell et al., 2011), autoimmunity (Chuprin et al., 2015) and mitochondrial biogenesis (Milne et al., 2007).”
BackgroundSignificance of Thiazole-based Heterocycles for Bioactive Systems
Pola, S. (2016) · InTech eBooks · doi:10.5772/62077 · Cited by 56
“For example, thiazolo[4,5b]pyridines have confirmed actions as serine protease factor Xa (fXa) inhibitors for thrombosis [162], as metabotropic glutamate receptor 5 (mGluR5) antagonists for several CNS syndromes [163], as histamine H3-receptor antagonists Bicyclic nitrog n, sulfur - containing het rocycles, suc a Thia…”
Park, S.-J., Ahmad, F., Um, J.-H., Brown, A. L., Xu, X., Kang, H., Ke, H., Feng, X., Ryall, J., Philp, A., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.03.019 · Cited by 44
“, 2015) and the serum concentration of SRT1720 in mice treated with SRT1720 (~1 μM) (Milne et al., 2007).”
BackgroundMethodInfluentialSelf-citationIncrease of enzyme activity through specific covalent modification with fragments
Darby, J. F., Atobe, M., Firth, J. D., Bond, P. S., Davies, G. J., O’Brien, P., & Hubbard, R. E. (2017) · Chemical Science · doi:10.1039/c7sc01966a · Cited by 48
Cai, G., Wang, H., Jung, Y. K., Xu, Z., Zhang, J., He, J., Wang, D., Shin, J., Kaewmanee, R., Nabanita, S., et al. (2020) · Composites Part B Engineering · doi:10.1016/j.compositesb.2020.107802 · Cited by 45
“, berries, peanuts and grapes), which not only possesses outstanding antibacterial performances but also has osteogenic activity [18].”
BackgroundZhou, F., Liu, Q., Zhang, L., Zhu, Q., Wang, S., Zhu, K., Deng, R., Liu, Y., Yuan, G., Wang, X. D., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02960-6 · Cited by 46
Understanding the link between cancer and neurodegeneration
Driver, J. A. (2011) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2011.11.007 · Cited by 47
Costantino, S., Mengozzi, A., Velagapudi, S., Mohammed, S. A., Gorica, E., Akhmedov, A. T., Mongelli, A., Pugliese, N. R., Masi, S., Virdis, A., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02057-2 · Cited by 47
“Calorie restriction is a potent Sirt1 activator [55], and some established drugs, such as metformin and atorvastatin, upregulated Ampk1 and Sirt1 in H9c2 cardiomyocytes and heart tissue [56].”
BackgroundStructure-Based Design of Pseudopeptidic Inhibitors for SIRT1 and SIRT2
Huhtiniemi, T., Salo, H. S., Suuronen, T., Poso, A., Salminen, A., Leppänen, J., Jarho, E., & Lahtela-Kakkonen, M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200590k · Cited by 44
Leontieva, O. V., Paszkiewicz, G., Demidenko, Z. N., & Blagosklonny, M. V. (2013) · Cell Death & Disease · doi:10.1038/cddis.2012.202 · Cited by 44
White, A. T., McCurdy, C. E., Philp, A., Hamilton, D. L., Johnson, C. D., & Schenk, S. (2013) · Diabetologia · doi:10.1007/s00125-013-2912-2 · Cited by 50
“Mice with whole-body overexpression of SIRT1 demonstrate a metabolic phenotype similar to that seen with energy intake restriction (EnR) [4, 5], while pharmacological activation of SIRT1 improves skeletal muscle insulin sensitivity in rodent models of insulin resistance [6, 7].”
Self-citationZhang, J., Hong, D., Zhang, C. W., Sun, X., Wang, Z., Shi, Y., Liu, J., Shen, G., Zhang, Y., Cheng, J., et al. (2014) · Cancer Science · doi:10.1111/cas.12364 · Cited by 47
Akieda‐Asai, S., Zaima, N., Ikegami, K., Kahyo, T., Yao, I., Hatanaka, T., Iemura, S.-I., Sugiyama, R., Yokozeki, T., Eishi, Y., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011755 · Cited by 49
“Under fed conditions, activation of SIRT1 improves insulin sensitivity [46,47].”
BackgroundWang, W., Shang, C., Zhang, W., Jin, Z., Yao, F., He, Y., Wang, B., Li, Y., Zhang, J., & Lin, R. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.09.208 · Cited by 48
Resveratrol is neuroprotective because it is not a direct activator of Sirt1—A hypothesis
Tang, B. L. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.12.007 · Cited by 51
Zhang, Y., He, L. R., Tu, M., Huang, M., Chen, Y., Pan, D., Peng, J., & Shen, X. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105629 · Cited by 45
Human sports drug testing by mass spectrometry
Schänzer, W., & Thevis, M. (2015) · Mass Spectrometry Reviews · doi:10.1002/mas.21479 · Cited by 46
Diabetic complications in pregnancy: is resveratrol a solution?
Singh, C. K., Kumar, A., LaVoie, H. A., DiPette, D. J., & Singh, U. S. (2013) · Experimental Biology and Medicine · doi:10.1177/1535370212473704 · Cited by 52
High-fat and obesogenic diets: current and future strategies to fight obesity and diabetes
Teodoro, J. S., Varela, A. T. I. F., Rolo, A. P., & Palmeira, C. M. (2014) · Genes & Nutrition · doi:10.1007/s12263-014-0406-6 · Cited by 51
Polyphenols from red wine are potent modulators of innate and adaptive immune responsiveness
Magrone, T., & Jirillo, E. (2010) · Proceedings of The Nutrition Society · doi:10.1017/s0029665110000121 · Cited by 48
“increased GLUT-4 expression and reduced endothelin expression and cardiac apoptosis in a genetic model of type-2 diabetes((87)); increased insulin sensitivity caused by a decrease of the blood glucose level in mice fed a high-energy diet((88)); attenuation of diabetic nephropathy in rats((89)); protection of the brain…”
BackgroundLi, J., Zhong, Z., Yuan, J., Chen, X., Huang, Z., & Wu, Z.-Y. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.01.022 · Cited by 43
A natural product solution to aging and aging-associated diseases
Yang, C., Zhang, W., Dong, X., Fu, C., Yuan, J., Xu, M., Liang, Z. C., Qiu, C., & Xu, C. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107673 · Cited by 45
Deng, X., Cheng, J., Zhang, Y., Li, N., & Chen, L. (2009) · Acta Diabetologica · doi:10.1007/s00592-009-0159-7 · Cited by 45
“Currently, small molecule activators of SIRT1 have been used as therapeutics for the treatment of type 2 diabetes [32].”
BackgroundSirtuin1-p53: A potential axis for cancer therapy
Yin, J., Lu, X.-T., Hou, M.-L., Cao, T., & Tian, Z. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115543 · Cited by 45
Carrillo, A. K., Guiguemde, W. A., & Guy, R. K. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.066 · Cited by 45
Therapeutic targets to reduce cardiovascular disease in type 2 diabetes
Desouza, C. V., & Fonseca, V. A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2872 · Cited by 44
Lysine Deacetylase (KDAC) Regulatory Pathways: an Alternative Approach to Selective Modulation
Dyke, M. W. V. (2014) · ChemMedChem · doi:10.1002/cmdc.201300444 · Cited by 49
Cross Regulation of Sirtuin 1, AMPK, and PPARγ in Conjugated Linoleic Acid Treated Adipocytes
Jiang, S., Wang, W., Miner, J., & Fromm, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048874 · Cited by 42
“Amongst the chemicals that affect the activity of sirtuins, the activator SRT1720 preferentially activates SIRT1 [40], while sirtinol and nicotinamide are used as general sirtuin inhibitors that do not inhibit class I/II deacetylases [41].”
Metadata
- Authors
- Milne, J. C., Lambert, P. D., Schenk, S., Carney, D. P., Smith, J. J., Gagne, D. J., Jin, L., Boss, O., Perni, R. B., Vu, C. B., Bemis, J. E., Xie, R., Disch, J. S., Ng, P. Y., Nunes, J. J., Lynch, A. V., Yang, H., Galonek, H., Israelian, K., Choy, W., Iffland, A., Lavu, S., Medvedik, O., Sinclair, D. A., Olefsky, J. M., Jirousek, M. R., Elliott, P. J., & Westphal, C. H.
- Affiliations
- University of California San Diego (US)
- Harvard University (US)
- Corresponding author
- Westphal, Christoph H.
- ORCID
- Venue
- Nature
- Published
- 2007-11-29
- Volume
- 450
- Issue
- 7170
- Pages
- 712-716
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2753457
- OpenAlex
- W2116350182
- Cited by
- 1,707
- References
- 27
- Citations by year
- 2026: 38 · 2025: 43 · 2024: 55 · 2023: 55 · 2022: 68 · 2021: 100 · 2020: 80 · 2019: 75 · 2018: 82 · 2017: 69 · 2016: 92 · 2015: 89 · 2014: 110 · 2013: 119 · 2012: 126
- FWCI
- 55.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute on Aging (P01AG027916, R01AG028730, R01AG019719)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- SIRT1, small molecule activators, type 2 diabetes, insulin resistance, caloric restriction mimetics, resveratrol, NAD+-dependent deacetylase, allosteric site, glucose homeostasis, mitochondrial function, obesity, aging, drug screening
- MeSH terms
- Resveratrol, Acetylation, Allosteric Site, Animals, Blood Glucose, Cell Line, Diabetes Mellitus, Type 2, Dietary Fats, Disease Models, Animal, Drosophila melanogaster, Heterocyclic Compounds, 4 or More Rings, Humans, Insulin, Male, Mitochondria, Rats, Zucker, Stilbenes, Rats, Sprague-Dawley, Catalytic Domain, Caloric Restriction, Sirtuins, Mice, Rats, Sirtuin 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.